2seventy bio, Inc. (NASDAQ:TSVT) Shares Sold by Brighton Jones LLC

Brighton Jones LLC trimmed its stake in 2seventy bio, Inc. (NASDAQ:TSVT) by 38.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 11,366 shares of the company’s stock after selling 7,070 shares during the quarter. Brighton Jones LLC’s holdings in 2seventy bio were worth $54,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. SkyView Investment Advisors LLC grew its holdings in shares of 2seventy bio by 25.0% in the 2nd quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company’s stock worth $48,000 after acquiring an additional 2,500 shares during the last quarter. Nisa Investment Advisors LLC acquired a new position in shares of 2seventy bio in the 2nd quarter worth $52,000. SG Americas Securities LLC acquired a new position in shares of 2seventy bio in the 3rd quarter worth $80,000. BBR Partners LLC grew its holdings in shares of 2seventy bio by 66.7% in the 2nd quarter. BBR Partners LLC now owns 25,000 shares of the company’s stock worth $96,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Public Employees Retirement System of Ohio boosted its position in shares of 2seventy bio by 2,637.0% in the first quarter. Public Employees Retirement System of Ohio now owns 27,370 shares of the company’s stock worth $146,000 after buying an additional 26,370 shares during the period. 93.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Morgan Stanley decreased their target price on 2seventy bio from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, 2seventy bio has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Insider Buying and Selling at 2seventy bio

In other 2seventy bio news, insider Jessica Snow sold 7,816 shares of the business’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $4.32, for a total value of $33,765.12. Following the transaction, the insider now owns 156,330 shares in the company, valued at $675,345.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 7.20% of the company’s stock.

2seventy bio Price Performance

Shares of NASDAQ TSVT opened at $4.85 on Monday. The business’s 50-day moving average price is $4.76 and its two-hundred day moving average price is $4.51. 2seventy bio, Inc. has a one year low of $1.53 and a one year high of $6.40. The company has a market capitalization of $249.31 million, a P/E ratio of -1.11 and a beta of 1.77.

2seventy bio (NASDAQ:TSVT) last issued its earnings results on Wednesday, August 7th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.06. 2seventy bio had a negative return on equity of 66.01% and a negative net margin of 354.16%. The firm had revenue of $8.97 million for the quarter, compared to the consensus estimate of $11.43 million. On average, equities analysts anticipate that 2seventy bio, Inc. will post -1.23 EPS for the current year.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.